THE ARIEL3 CLINICAL TRIAL

ARIEL3 is a pivotal, phase 3, randomized, double-blind study comparing the effects of rucaparib versus placebo, to evaluate whether rucaparib given as a **maintenance treatment** to platinum-sensitive ovarian cancer patients can extend the period of time for which the disease is controlled after a complete or partial response to platinum-based chemotherapy. Rucaparib is an oral, small-molecule poly (ADP-ribose) polymerase (PARP) inhibitor.

STUDY POPULATION

564 Women with **recurrent ovarian cancer** who met key eligibility criteria

Primary Endpoint: Investigator-assessed Progression-Free Survival (PFS) by RECIST[1]

Three levels of step-down included in the primary and key secondary efficacy analysis:

Step 1: BRCA mutant (BRCAmut; n=196)	Step 2: Homologous recombination deficient (HRD) (inclusive of BRCAmut; n=354)	Step 3: All patients enrolled in study (intent-to-treat [ITT] or "all-comers"[2]; n=564)

RESULTS



"We believe this is a very important step forward for women with advanced ovarian cancer. These results underscore the potential to provide enduring and important clinical benefit to these women, regardless of their tumor genetics."

- Patrick J. Mahaffy, President and CEO of Clovis Oncology

- **The most common treatment-emergent grade ≥3 adverse events among all patients treated with rucaparib in the ARIEL3 study were anemia/decreased hemoglobin (19%), increase in ALT/AST (10%), neutropenia (7%), asthenia/fatigue (7%), thrombocytopenia (5%), vomiting (4%) and nausea (4%), consistent with prior studies of rucaparib in the treatment setting.**

More information on this trial (NCT01968213) is available at ClinicalTrials.gov

ARIEL3 is sponsored by Clovis Oncology, Inc., Boulder, CO, USA.

[1] Response Evaluation Criteria in Solid Tumors (RECIST)
[2] "All-comers" are any patients that entered the trial
[3] Key secondary endpoint
[4] Not reached

CLOVIS ONCOLOGY